English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background & Aims  Hepatocellular carcinoma ( HCC ) is the second most common cause of cancer deaths worldwide. The global  HCC BRIDGE  study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with  HCC , from diagnosis to death.    Methods  Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with  HCC  at participating institutions.    Results  Forty‐two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first  HCC  treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first  HCC  treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively ( P  <   0.0001).    Conclusions  Initial results from the  BRIDGE  study confirm previously reported regional trends in patient demographic characteristics and  HCC  risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier  HCC  diagnosis worldwide.

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study